Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.

about

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

P2860

Q52723939-14B5C747-A3AE-4217-92B1-E477A7576F84 Q55178886-CA4A9DD3-E17F-42DB-B0A6-68326CACF181

P2860

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.

Item

http://www.wikidata.org/entity/Q38651333

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Deciphering mechanisms of acqu ...... by computational simulations.

@en

type

Item

label

Deciphering mechanisms of acqu ...... by computational simulations.

@en

prefLabel

Deciphering mechanisms of acqu ...... by computational simulations.

@en

P1476

Deciphering mechanisms of acqu ...... C by computational simulations

@en

P2093

Bin Zou

http://www.w3.org/2001/XMLSchema#string

Debby D Wang

http://www.w3.org/2001/XMLSchema#string

Hong Yan

http://www.w3.org/2001/XMLSchema#string

Lichun Ma

http://www.w3.org/2001/XMLSchema#string

Lijiang Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The Protein Data Bank

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

P2888

s41598-017-06632-y

P304

6595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-06632-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Victor Ho Fun Lee

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090836332

http://www.w3.org/2001/XMLSchema#string

P698

28747773

http://www.w3.org/2001/XMLSchema#string

P932

5529360

http://www.w3.org/2001/XMLSchema#string

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.

about

P2860

P2860

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932